Literature DB >> 7701279

Childhood-onset schizophrenia: history of the concept and recent studies.

H E Remschmidt1, E Schulz, M Martin, A Warnke, G E Trott.   

Abstract

Schizophrenic disorders in childhood are rare: 0.1-1 percent of all schizophrenic disorders manifest themselves before age 10, and 4 percent before age 15. There is, however, a remarkable increase in schizophrenia during adolescence. Age and developmental stage also influence symptoms, course, and outcome. The evidence for a male preponderance in the very early-onset group (< 14) does not apply for adolescents over age 14. The presence of positive and negative precursor symptoms can be demonstrated in child and adolescent schizophrenia before the first clinical manifestation leading to inpatient treatment. With regard to pharmacologic treatment, atypical neuroleptics such as clozapine can be used successfully. As to outcome, schizophrenic psychoses with early manifestation have a poor prognosis. The patients' premorbid personality also seems to be of great importance: A poor prognosis can be found in patients who were cognitively impaired, shy, introverted, and withdrawn before the beginning of their psychotic state.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7701279     DOI: 10.1093/schbul/20.4.727

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  19 in total

1.  Deficient maturation of aspects of attention and executive functions in early onset schizophrenia.

Authors:  Jens Richardt M Jepsen; Birgitte Fagerlund; Anne Katrine Pagsberg; Anne Marie R Christensen; Merete Nordentoft; Erik L Mortensen
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-08-01       Impact factor: 4.785

2.  Forty-two-years later: the outcome of childhood-onset schizophrenia.

Authors:  H Remschmidt; M Martin; C Fleischhaker; F M Theisen; K Hennighausen; C Gutenbrunner; E Schulz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  Age Matters: an Atypical Association Between Polymorphism of MTHFR and Clinical Phenotypes in Children with Schizophrenia.

Authors:  Lin Wan; Yuhong Li; Yuming Zhou; Rena Li; Yi Zheng
Journal:  J Mol Neurosci       Date:  2019-07-13       Impact factor: 3.444

Review 5.  Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia.

Authors:  Bernard Crespi; Philip Stead; Michael Elliot
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-01       Impact factor: 11.205

6.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

7.  Study of childhood onset schizophrenia (COS) using SPECT and neuropsychological assessment.

Authors:  Savita Malhotra; Nitin Gupta; Anish Bhattacharya; Mehak Kapoor
Journal:  Indian J Psychiatry       Date:  2006-10       Impact factor: 1.759

8.  Co-occurrence of autism, childhood psychosis, and intellectual disability associated with a de novo 3q29 microdeletion.

Authors:  Angela Sagar; Jeffrey R Bishop; D Clare Tessman; Steve Guter; Christa L Martin; Edwin H Cook
Journal:  Am J Med Genet A       Date:  2013-02-26       Impact factor: 2.802

9.  Medication adherence for children and adolescents with first-episode psychosis following hospitalization.

Authors:  Robin E Gearing; Alice Charach
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-04-21       Impact factor: 4.785

10.  Impact of sex and gonadal steroids on neonatal brain structure.

Authors:  Rebecca C Knickmeyer; Jiaping Wang; Hongtu Zhu; Xiujuan Geng; Sandra Woolson; Robert M Hamer; Thomas Konneker; Martin Styner; John H Gilmore
Journal:  Cereb Cortex       Date:  2013-05-19       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.